Last reviewed · How we verify
ARIPiprazole 30 MG
Aripiprazole 30 mg, marketed by Ain Shams University, holds a position in the psychiatric treatment landscape. The key composition patent is set to expire in 2028, providing a period of market exclusivity. The primary risk is the lack of disclosed revenue data, which may affect investment and market confidence.
At a glance
| Generic name | ARIPiprazole 30 MG |
|---|---|
| Sponsor | Ain Shams University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of Esketamine Nasal Spray vs.Aripiprazole in Treat.Resistant Major Depressive Disorder in Elderly Patients (PHASE3)
- Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone (PHASE1)
- RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder (PHASE2)
- Personalized Indications for CBT and Antidepressants in Treating Depression (PHASE4)
- Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT) (PHASE3)
- Impact of Aripiprazole Once Monthly Medications on Changes in Brain Structure and Metabolism (PHASE4)
- Add-on MEmaNtine to Dopamine Modulation to Improve Negative Symptoms at First Psychosis (PHASE1)
- Aripiprazole for Bipolar Disorder and Alcohol Use Disorder (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ARIPiprazole 30 MG CI brief — competitive landscape report
- ARIPiprazole 30 MG updates RSS · CI watch RSS
- Ain Shams University portfolio CI